JP2023052910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023052910A5 JP2023052910A5 JP2023015725A JP2023015725A JP2023052910A5 JP 2023052910 A5 JP2023052910 A5 JP 2023052910A5 JP 2023015725 A JP2023015725 A JP 2023015725A JP 2023015725 A JP2023015725 A JP 2023015725A JP 2023052910 A5 JP2023052910 A5 JP 2023052910A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- group
- formula
- salt
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113314A JP7754361B2 (ja) | 2017-04-28 | 2025-07-03 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| JP2025166056A JP2025185050A (ja) | 2017-04-28 | 2025-10-02 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017090679 | 2017-04-28 | ||
| JP2017090679 | 2017-04-28 | ||
| JP2019514691A JP7222347B2 (ja) | 2017-04-28 | 2018-04-27 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| PCT/JP2018/017345 WO2018199337A1 (ja) | 2017-04-28 | 2018-04-27 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514691A Division JP7222347B2 (ja) | 2017-04-28 | 2018-04-27 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113314A Division JP7754361B2 (ja) | 2017-04-28 | 2025-07-03 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023052910A JP2023052910A (ja) | 2023-04-12 |
| JP2023052910A5 true JP2023052910A5 (https=) | 2023-04-25 |
| JP7708133B2 JP7708133B2 (ja) | 2025-07-15 |
Family
ID=63918939
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514691A Active JP7222347B2 (ja) | 2017-04-28 | 2018-04-27 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| JP2023015725A Active JP7708133B2 (ja) | 2017-04-28 | 2023-02-03 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| JP2025113314A Active JP7754361B2 (ja) | 2017-04-28 | 2025-07-03 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| JP2025166056A Pending JP2025185050A (ja) | 2017-04-28 | 2025-10-02 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514691A Active JP7222347B2 (ja) | 2017-04-28 | 2018-04-27 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113314A Active JP7754361B2 (ja) | 2017-04-28 | 2025-07-03 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| JP2025166056A Pending JP2025185050A (ja) | 2017-04-28 | 2025-10-02 | 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12024549B2 (https=) |
| EP (2) | EP3617235B1 (https=) |
| JP (4) | JP7222347B2 (https=) |
| KR (3) | KR20240046307A (https=) |
| CN (1) | CN110637036A (https=) |
| AU (2) | AU2018259856B2 (https=) |
| CA (1) | CA3061467A1 (https=) |
| WO (1) | WO2018199337A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7291395B2 (ja) * | 2017-06-16 | 2023-06-15 | 国立大学法人 鹿児島大学 | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| KR102921757B1 (ko) * | 2018-06-14 | 2026-02-03 | 아지노모토 가부시키가이샤 | 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염 |
| JPWO2019240288A1 (ja) * | 2018-06-14 | 2021-07-26 | 味の素株式会社 | 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩 |
| JPWO2020090979A1 (ja) * | 2018-10-31 | 2021-09-24 | 味の素株式会社 | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 |
| AU2020210506B2 (en) * | 2019-01-23 | 2025-02-13 | AbTis Co., Ltd. | Compound for preparation of antibody-payload conjugate and use thereof |
| EP3936501B1 (en) | 2019-03-08 | 2025-12-31 | ABTIS Co., Ltd. | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG conjugate serving as a specific example thereof |
| TWI886164B (zh) | 2019-10-24 | 2025-06-11 | 國立大學法人鹿兒島大學 | 1價ccap生成物之製造方法 |
| JP2023501720A (ja) * | 2019-11-18 | 2023-01-18 | クレオ ファーマシューティカルズ， インコーポレイテッド | 指向性コンジュゲーション技術 |
| AU2020396219A1 (en) * | 2019-12-03 | 2022-07-14 | Debiopharm Research & Manufacturing S.A. | Reactive conjugates |
| WO2022078566A1 (en) * | 2020-10-12 | 2022-04-21 | Debiopharm Research & Manufacturing S.A. | Reactive conjugates |
| JP7670072B2 (ja) | 2021-01-18 | 2025-04-30 | 味の素株式会社 | 化合物またはその塩、およびそれらにより得られる抗体 |
| CA3208296A1 (en) | 2021-01-18 | 2022-07-21 | Ajinomoto Co., Inc. | Compound or salt thereof, and antibody obtained by using the same |
| CA3212822A1 (en) * | 2021-03-11 | 2022-09-15 | Ajinomoto Co., Inc. | Compound or salt thereof, and antibody obtained by using the same |
| WO2022196675A1 (ja) | 2021-03-16 | 2022-09-22 | 味の素株式会社 | 複合体またはその塩、およびその製造方法 |
| CN113292633B (zh) * | 2021-05-13 | 2023-08-29 | 中国科学技术大学 | 可见光诱导甘氨酸衍生物的肼化修饰方法 |
| CA3219517A1 (en) * | 2021-05-17 | 2022-11-24 | Wieslaw Kazmierski | Agents for directed conjugation techniques and conjugated products |
| US20250108124A1 (en) * | 2021-05-19 | 2025-04-03 | Biohaven Therapeutics Ltd. | Antibody drug conjugates using mates technology for delivering cytotoxic agents |
| AU2022286137A1 (en) | 2021-06-01 | 2023-12-14 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| EP4366781A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| WO2023281480A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
| JPWO2023038082A1 (https=) | 2021-09-08 | 2023-03-16 | ||
| CA3234692A1 (en) | 2021-09-30 | 2023-04-06 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof |
| AU2022353331A1 (en) | 2021-09-30 | 2024-04-11 | Ajinomoto Co., Inc. | Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| KR20230132640A (ko) | 2022-03-04 | 2023-09-15 | 앱티스 주식회사 | 티올 반응성 에디티브를 이용한 항체-약물 컨쥬게이트의 제조 수율을 높이는 방법 |
| CN116836235A (zh) * | 2022-03-25 | 2023-10-03 | 中国科学院上海药物研究所 | 亲和片段导向的可裂解片段，其设计、合成及在制备定点药物偶联物中的应用 |
| WO2023234416A1 (ja) | 2022-06-02 | 2023-12-07 | 味の素株式会社 | 親和性物質、化合物、抗体およびそれらの塩 |
| KR20240125071A (ko) | 2022-11-01 | 2024-08-19 | 앱티스 주식회사 | Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트 |
| US20240424127A1 (en) | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| AU2024234975A1 (en) * | 2023-03-15 | 2025-09-18 | Kagoshima University | Method for producing radiolabeled antibody, radiolabeled antibody, and radiopharmaceutical |
| WO2024210154A1 (ja) | 2023-04-04 | 2024-10-10 | 味の素株式会社 | 抗体および機能性物質のコンジュゲート、抗体誘導体ならびに化合物、またはそれらの塩 |
| CN121039143A (zh) | 2023-04-05 | 2025-11-28 | 味之素株式会社 | 抗体和功能性物质的缀合物或其盐、以及具有硫醇基的抗体中间体或其盐 |
| WO2025041097A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250144234A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics Inc. | RNA for In vivo Transfection with Increased Expression |
| US20250332281A2 (en) | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025158412A1 (en) | 2024-01-26 | 2025-07-31 | Biohaven Therapeutics Ltd. | BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025181697A1 (en) | 2024-02-26 | 2025-09-04 | Biohaven Therapeutics Ltd. | Bifunctional degraders of anti-pla2r antibody |
| WO2025210538A1 (en) | 2024-04-02 | 2025-10-09 | Biohaven Therapeutics Ltd. | Bifunctional degraders |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026028158A1 (en) | 2024-07-31 | 2026-02-05 | Biohaven Therapeutics Ltd. | Targeted degradation of anti-aav antibodies to enable aav-based gene therapy |
| WO2026028159A1 (en) | 2024-07-31 | 2026-02-05 | Biohaven Therapeutics Ltd. | Bifunctional degraders for the treatment of graves' disease |
| KR20260026725A (ko) | 2024-08-20 | 2026-02-27 | 주식회사 엘지에너지솔루션 | 배터리의 전극 탭 검사 장치 및 방법 |
| WO2026058917A1 (ja) * | 2024-09-10 | 2026-03-19 | 味の素株式会社 | 抗体親和性物質を含む化合物、修飾抗体およびそれらの塩ならびに抗体誘導体または抗体－機能性物質コンジュゲートの製造方法 |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| JP3825502B2 (ja) * | 1996-06-11 | 2006-09-27 | 日本油脂株式会社 | 修飾蛋白質の製造法及びコンタクトレンズ用汚れ除去剤 |
| AU1519699A (en) * | 1997-11-07 | 1999-05-31 | Conjuchem, Inc. | Affinity markers for human serum albumin |
| EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP1757701A1 (en) | 1999-12-24 | 2007-02-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| DE10162773A1 (de) | 2001-12-20 | 2003-07-10 | Knf Flodos Ag Sursee | Dosierpumpe |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| EP1853294A4 (en) | 2005-03-03 | 2010-01-27 | Covx Technologies Ireland Ltd | ANTIANGIOGENIC COMPOUNDS |
| CA2614145A1 (en) | 2005-07-05 | 2007-01-11 | Ribomic Inc. | Nucleic acid capable of binding to immunoglobulin g and use thereof |
| US20090041674A1 (en) | 2006-02-28 | 2009-02-12 | William Alexander Jones | Targeted iron oxide nanparticles |
| WO2008054030A1 (fr) | 2006-11-02 | 2008-05-08 | Kagoshima University | Peptide liant l'igg |
| EP2368908A3 (en) | 2006-11-10 | 2011-10-12 | CovX Technologies Ireland Limited | Anti- angiogenic compounds |
| US20130028920A1 (en) * | 2010-03-31 | 2013-01-31 | Universite De Geneve | Stabilized antibody preparations and uses thereof |
| JP5994068B2 (ja) | 2011-08-24 | 2016-09-21 | 国立大学法人 鹿児島大学 | ＩｇＧ結合性ペプチド及びそれによるＩｇＧの検出および精製方法 |
| WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| US10071170B2 (en) | 2013-06-24 | 2018-09-11 | Ablbio | Antibody-drug conjugate having improved stability and use thereof |
| WO2015191883A1 (en) * | 2014-06-12 | 2015-12-17 | Dophen Biomedical | Homogenous antibody drug conjugates via enzymatic methods |
| US20160000933A1 (en) * | 2014-07-01 | 2016-01-07 | Andrei POLUKHTIN | Conjugated biological molecules and their preparation |
| JP5827769B1 (ja) | 2015-03-27 | 2015-12-02 | 義徳 川窪 | 掃除装置 |
| ES3058443T3 (es) | 2015-05-20 | 2026-03-10 | Univ Kagoshima | Modificación específica de anticuerpo con péptido de unión a IgG |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| UA124622C2 (uk) | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
| JP7020403B2 (ja) * | 2016-05-02 | 2022-02-16 | 味の素株式会社 | アジド基含有Ｆｃタンパク質 |
| DK3470418T3 (da) * | 2016-06-13 | 2024-09-30 | Univ Kagoshima | Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid |
-
2018
- 2018-04-27 AU AU2018259856A patent/AU2018259856B2/en active Active
- 2018-04-27 CA CA3061467A patent/CA3061467A1/en active Pending
- 2018-04-27 WO PCT/JP2018/017345 patent/WO2018199337A1/ja not_active Ceased
- 2018-04-27 KR KR1020247010619A patent/KR20240046307A/ko active Pending
- 2018-04-27 KR KR1020197031664A patent/KR20200002858A/ko not_active Ceased
- 2018-04-27 EP EP18791007.0A patent/EP3617235B1/en active Active
- 2018-04-27 JP JP2019514691A patent/JP7222347B2/ja active Active
- 2018-04-27 KR KR1020247022678A patent/KR20240111015A/ko active Pending
- 2018-04-27 CN CN201880027775.4A patent/CN110637036A/zh active Pending
- 2018-04-27 EP EP25168802.4A patent/EP4603507A3/en active Pending
-
2019
- 2019-10-25 US US16/663,791 patent/US12024549B2/en active Active
-
2023
- 2023-02-03 JP JP2023015725A patent/JP7708133B2/ja active Active
-
2024
- 2024-05-16 US US18/666,145 patent/US20240366783A1/en active Pending
-
2025
- 2025-07-03 JP JP2025113314A patent/JP7754361B2/ja active Active
- 2025-07-22 AU AU2025206404A patent/AU2025206404A1/en active Pending
- 2025-10-02 JP JP2025166056A patent/JP2025185050A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023052910A5 (https=) | ||
| JP7417432B2 (ja) | 新規リンカー、その製造方法およびその応用 | |
| Sato et al. | Ligand-directed selective protein modification based on local single-electron-transfer catalysis. | |
| Guichard et al. | Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. | |
| AU2018259856B2 (en) | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof | |
| US20210040177A1 (en) | Multi-Specific Molecules | |
| US20090234105A1 (en) | Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition | |
| US6821529B2 (en) | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers | |
| EP0093652B1 (fr) | Toxine synthétique ST, son procédé de préparation et son application comme agent vaccinant | |
| JP2019502684A5 (https=) | ||
| JP2022527247A5 (https=) | ||
| US6403324B1 (en) | Affinity labeling libraries with tagged leaving group | |
| JP2020506685A5 (https=) | ||
| WO1991017173A1 (en) | Molecular recognition units | |
| JPWO2022191283A5 (https=) | ||
| IL100811A (en) | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock | |
| JPWO2023234416A5 (https=) | ||
| CA2162157A1 (en) | Polyoxime compounds and their preparation | |
| JPH03501622A (ja) | 蛋白誘導体及びその調製法 | |
| EP1204865A1 (fr) | Composes synthetiques portant deux epitopes pour immunodosages | |
| RS64205B1 (sr) | Antitelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primene | |
| EP0920443B1 (en) | Activated peptides and conjugates | |
| IE910750A1 (en) | A monoclonal antibody against complexed and noncomplexed complexing agents for removing heavy metals from aqueous solutions and for analysis | |
| Hussein et al. | Synthesis of nickel-chelating fluorinated lipids for protein monolayer crystallizations | |
| CN101918841B (zh) | 肽-脂构造及其在诊断和治疗用途中的应用 |